Comparative pharmacokinetics of six components in normal and rheumatoid arthritis rats after intragastrical administration of Qianghuo Shengshi Decoction granules by LC-MS/MS

Objective:To investigate the plasma pharmacokinetics of six representative components(nodakenin,osthole,5-O-methylvisammioside,ferulic acid,liquiritigenin,and liquiritin),which were the ingredients of Qianghuo Shengshi Decoction(QSD)granules,in normal and rheumatoid arthritis(RA)rats administrated QSD granules intragastrically.Methods:A rapid and accurate ultra-high performance liquid chromatography-tandem mass spectrometry(LC-MS/MS)method was developed for the simultaneous determination of six components in plasma,and it showed a good specificity,linearity,intra-day and inter-day precision,intra-day and inter-day accuracy,extraction recovery,stability,and the less matrix effect.Results:The validated LC-MS/MS method was successfully used to compare the plasma pharmacokinetics of six ingredients between normal and RA rats after intragastrical administration of QSD granules and differences in the pharmacokinetics were found in two types of rats.The absorption rate in the RA rats was lower for nodakenin,osthole,5-O-methylvisammioside,liquiritigenin and liquiritin than in the normal group,while the absorption rate of ferulic acid remained constant in two groups.In comparison with the normal rats,the exposure concentration of nodakenin was higher and that of other five components except for nodakenin was lower under pathological conditions.Additionally,the absorptive amount of nodakenin,osthole,5-O-methylvisammioside and liquiritin was increased and that of ferulic acid and liquiritigenin was reduced in the RA rats than in the normal rats.Compared with the normal rats,the retention time of nodakenin,ferulic acid and liquiritin was reduced in vivo,whereas the retention time of osthole,5-O-methylvisammioside and liquiritigenin was raised in the body for the RA rats.In contrast to the normal rats,the data demonstrated an increase in the elimination velocity of nodakenin and a decrease in the elimination velocity of the other five components except for nodakenin in the pathological state.Conclusion:This study showed that the pharmacokinetic behavior of the six components,nodakenin,osthole,5-O-methylvisammioside,ferulic acid,liquiritigenin,and liquiritin,is different in vivo between normal and pathological states of rats,and this research provided the necessary experimental data to explain the pharmacokinetics of QSD granules in both normal and pathological states and provide some references for its clinical application at some level.

Refractory Products

Products： high purity oxide products, high quality silicon carbide bricks, functional refractories for metallurgy, monolithic refractories, composite materials, special ceramic materials, refractory ceramic fibres, high temperature testing apparatus, LIRR Huoshen Brand medical apparatus.

Clinical Study on Yishen Qufeng Shengshi Recipe (益肾祛风胜湿方) for Glomerular Proteinuria Patients： A Randomized Controlled Trial

Objective： To explore the therapeutic effect of Yishen Qufeng Shengshi Recipe （益肾祛风胜湿方, YQSR） in patients with glomerular proteinuria. Methods： A total of 145 patients with glomerular proteinuria were selected and randomly assigned to the treatment group （108 cases） and the control group （37 cases） according to a random number table in a ratio of 3：1. All patients received conventional and symptomatic treatment. In addition, patients in the treatment and control groups were given YQSR （200 mL, twice per day, orally） and losartan （50 mg/d orally）, respectively for 6 months. The 24-h urine protein quantity, blood urea nitrogen, and serum creatinine in the two groups were measured at multiple time points before and after treatment. Results： At the end of the study, 5 cases were lost to follow-up in the treatment group and 1 in the control group. Finally, the statistical data included 103 cases in the treatment group and 36 cases in the control group. The total effectiveness after 2, 4, and 6 months was 81.6% （84/103）, 87.4% （90/103）, and 92.2% （95/103）, respectively, in the treatment group and 47.2% （17/36）, 55.6% （20/36）, and 61.1% （22/36）, respectively, in the control group, with significant difference between the two groups （P〈0.01 at all observation points）. In the treatment group, the curative effect after 6 months was better than that after 2 months （P〈0.05）. The 24-h urine protein quantity was significantly lower in the treatment group at 3, 4, 5, and 6 months than that in the control group （P〈0.05 or P〈0.01, respectively）. Conclusion： YQSR could significantly reduce the amount of glomerular proteinuria in the early stage.